<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179656</url>
  </required_header>
  <id_info>
    <org_study_id>BP-HER2</org_study_id>
    <nct_id>NCT04179656</nct_id>
  </id_info>
  <brief_title>The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor</brief_title>
  <official_title>An Open-label, Phase 2 Study of Pyrotinib Maleate in Advanced Solid Tumors Patients With HER2( Erb-B2 Receptor Tyrosine Kinase 2)-Postive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Second Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib
      Maleate Tablets in patients with solid tumors with activating（harmful） HER2 mutations or with
      HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and /
      or fluorescence in situ hybridization (FISH) positive.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>at least 3 months</time_frame>
    <description>Objective response rate defined as the patients confirmed complete response or partial response under RECIST 1.0 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression-free survival estimated using Kaplan-Meier methods is defined as the time from registration to the earlier of death or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The first evaluation of treatment efficacy is the time fromcomplete response or partial response to the first assessment of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Objective response rate defined as the patients confirmed complete response or partial response or stable disease under RECIST 1.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Overall survival estimated using Kaplan-Meier methods is defined as the time from treatment initiation to death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events and Serious Adverse Events)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>From consent through 28 days following treatment completion (estimated 6 months)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Tumor</condition>
  <condition>HER2 Gene Mutation</condition>
  <condition>HER-2 Gene Amplification</condition>
  <condition>HER-2 Protein Overexpression</condition>
  <arm_group>
    <arm_group_label>Pyrotinib Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm for HER2-postive solid tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>400 mg administered orally, once daily, continuously in 21 day cycles</description>
    <arm_group_label>Pyrotinib Treatment</arm_group_label>
    <other_name>SHR1258</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients between the ages of 18 and 75;

          2. ECOG physical status score 0-2 points;

          3. The estimated total survival period is not less than 12 weeks;

          4. Patients with HER2-positive solid tumors confirmed by pathology and identified as
             advanced tumors by clinicians or centers;

          5. HER2 positive: refers to standard immunohistochemical staining (IHC) assay showing
             HER2 is 3+ and / or fluorescence in situ hybridization (FISH) positive or after second
             generation sequencing shows HER2 amplification and copy number ≥ 3, or There is a HER2
             activating mutation identified by the Molecular Oncology Committee (confirmed by the
             investigator at the test center) ;

          6. Imaging studies have at least one measurable lesion with a diameter ≥ 10 mm;

          7. Pilotinib has not been used for the past 3 months;

          8. The main organs function normally, they meet the following criteria:

               1. Blood routine examination criteria are to comply with:

                  ①.Hb≥100 g/L; ②.ANC ≥ 1.5 × 109 / L; ③.PLT≥75×109 /L;

               2. Biochemical tests are subject to the following criteria

                  ①.TBIL ≤ 1.5 × ULN (upper limit of normal value);

                  ②.ALT and AST ≤ 2.5 × ULN; if there is liver metastasis, ALT and AST ≤ 5 × ULN;

                  ③.Serum creatinine ≤ 1.5 × ULN, creatinine clearance ≥ 50ml / min (based on
                  Cockroft and Gault formula);

               3. Heart color ultrasound: Left ventricular ejection fraction (LVEF) ≥ 50%;

          9. The patient or his legal guardian understands the test procedure and content and signs
             an informed consent form (ICF) to provide true and effective information in accordance
             with the research and follow-up procedures;

        Exclusion Criteria:

          1. There is a third interstitial fluid that cannot be controlled by drainage or other
             methods, such as pleural effusion and ascites;

          2. It has many factors affecting the oral and absorption of drugs (such as inability to
             swallow, postoperative gastrointestinal resection, chronic diarrhea and intestinal
             obstruction);

          3. Those who have been confirmed to be allergic to the drug components of this program;

          4. Patients who are known to be pregnant or planning to become pregnant, or gestational
             age patients who are unwilling to take effective contraceptive measures throughout the
             trial;

          5. Patients with severe concomitant diseases or those considered by the investigator to
             be unsuitable for inclusion.

          6. The investigator believes that the subject may not be able to complete the study or
             may not be able to comply with the requirements of the study (for administrative
             reasons or for other reasons).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haitao Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Second Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haitao Wang</last_name>
    <phone>(022)28331788</phone>
    <email>peterrock2000@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LIli Wang</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Second Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

